NovoCure Limited (NVCR)

NovoCure Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	457.36	242.56	115.83	209.61	246.17	179.42
Short-Term Investments	416.38	669.8	854.1	728.9	607.9	148.77
Cash & Cash Equivalents	873.75	912.36	969.93	938.51	854.08	328.19
Cash Growth	-8.86%	-5.94%	3.35%	9.89%	160.24%	32.33%
Receivables	86.57	83.9	112.22	110.59	117.94	88.06
Inventory	42.39	38.15	29.38	24.43	27.42	23.7
Total Current Assets	1,003	1,034	1,112	1,074	999.44	439.95
Property, Plant & Equipment	103.82	97.7	68.96	53.88	41.63	34.6
Other Long-Term Assets	14.9	14.02	11.16	12.09	10.91	4.9
Total Long-Term Assets	118.72	111.72	80.12	65.97	52.54	39.5
Total Assets	1,121	1,146	1,192	1,139	1,052	479.45
Accounts Payable	84.32	94.39	85.2	72.6	53.65	86.31
Deferred Revenue	0	0	2.88	6.48	12.14	7.81
Other Current Liabilities	75.91	84.72	70.7	63.53	47.83	-7.81
Total Current Liabilities	160.23	179.12	158.78	142.6	113.61	86.31
Long-Term Debt	595.26	596.24	584.27	575.21	444.2	163.56
Other Long-Term Liabilities	6.58	8.28	7.43	11.19	17.65	11.78
Total Long-Term Liabilities	601.84	604.52	591.7	586.4	461.85	175.35
Total Liabilities	762.07	783.63	750.48	729	575.46	261.66
Total Debt	595.26	596.24	584.27	575.21	444.2	163.56
Debt Growth	1.53%	2.05%	1.57%	29.49%	171.57%	9.58%
Retained Earnings	-1,024.26	-985.5	-778.46	-685.93	-631.08	-650.89
Comprehensive Income	-4.15	-5.47	-2.43	-3.17	-3.83	-2.77
Shareholders' Equity	359.36	362.5	441.17	410.49	476.53	217.79
Net Cash / Debt	278.49	316.12	385.66	363.29	409.88	164.62
Net Cash / Debt Growth	-25.22%	-18.03%	6.16%	-11.37%	148.98%	66.71%
Net Cash Per Share	2.60	2.97	3.68	3.51	3.76	1.69
Working Capital	842.48	855.29	952.75	930.92	885.83	353.64
Book Value Per Share	3.35	3.41	4.21	3.97	4.72	2.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).